Imigran

Sumatriptan, the active ingredient in Imigran, is a Triptan (5‑HT1B/1D receptor agonist) presented as an unknown strength/oral tablet for oral use. It treats acute migraine attacks in adults.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imigran (sumatriptan) acts on the serotonergic pathway to relieve migraine and related headache disorders.

Migraine with aura: provides rapid relief of headache pain and associated symptoms. Migraine without aura: reduces the intensity and duration of an acute migraine episode. Cluster headache: alleviates acute attacks of episodic cluster headache in adults.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or face - Nausea or upset stomach - Dizziness or light‑headedness - Fatigue or drowsiness - Dry mouth

Serious or Rare Side Effects: - Coronary vasospasm or myocardial ischemia - Serotonin syndrome, especially with other serotonergic agents - Severe allergic reaction (anaphylaxis, angioedema) - Hypertension or sudden increase in blood pressure - Cardiac arrhythmias - Stroke or transient ischemic attack

Before using Imigran, consider the following precautions: - Cardiovascular assessment: evaluate history of heart disease or risk factors. - Hypertension: avoid use in uncontrolled high blood pressure. - Contraindicated in patients with ischemic heart disease, uncontrolled arrhythmias, or recent myocardial infarction. - Drug interactions: do not combine with MAO inhibitors, ergot derivatives, or other triptans. - Pregnancy and lactation: use only if clearly needed and prescribed by a physician. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Sumatriptan may interact with several drug classes.

Major Interactions (Avoid): - MAO inhibitors: risk of severe hypertension and serotonin syndrome. - Ergotamine or ergot derivatives: additive vasoconstriction can cause coronary events. - Other triptans: increased risk of vasospastic complications. - SSRIs, SNRIs, or other serotonergic agents: potential for serotonin syndrome. - Certain antihypertensives (e.g., ergot‑derived vasodilators): may blunt therapeutic effect.

Moderate Interactions (Monitor Closely): - Antihistamines and diphenhydramine: may enhance drowsiness. - Oral contraceptives: may slightly increase migraine frequency. - CYP3A4 inhibitors (e.g., ketoconazole): can raise sumatriptan plasma levels. - Herbal supplements containing serotonergic activity (e.g., St. John’s wort).